Protocol Ledger

NCT03605667 · Phase II · COMPLETED

Study of BHV-4157 in Alzheimer's Disease

Interventional Phase II clinical trial protocol NCT03605667 sponsored by Pfizer in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-31 Enrollment: 350 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03605667
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)350 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03605667
Protocol FieldVerified Registry Value
NCT IdentifierNCT03605667
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment350 participants (ACTUAL)
Registered Start Date2018-07-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI